The year 2019 saw significant advancement in the pharmaceutical sector in India. The year brought a change with the approval of numerous drugs for the treatment of a wide range of conditions. These approvals not only reflect the progress made in medicine but also enhance the quality of care available to patients. The 2019 approved drugs cater to conditions such as asthma, diabetes, HIV, rheumatoid arthritis, cancer, and more. In this article, you will get to know about the list of 2019 approved drugs in India approved by the CDSCO (Central Drugs Standard Control Organization).
What New 2019 Approved Drugs In India?
Basically, in 2019, India approved many new drugs like Fenspride, Hydrochloride for asthma, Bilastine for allergic rhino-conjunctivitis, and fingolimod for multiple sclerosis and so on. Still, if you are confused, then directly check out the table mentioned above.
Key Highlights of Drug Approvals in India in 2019
Get to know about the key highlights of the List of 2019 Approved Drugs in India. It is necessary to understand which drugs have been approved in the year. The highlights are as follows:
- Diversity of Therapeutic Areas – Drugs approved for conditions like diabetes, cancer, rheumatoid arthritis, and respiratory diseases.
- Innovative Treatments – New mechanisms of action in medications for chronic and rare conditions.
- Introduction of Biological and Targeted Therapies – Emphasis on drugs for conditions such as multiple sclerosis and hormone receptor-positive breast cancer.
List Of New Drugs Approved In 2019 CDSCO
Below you will get to know about the list of 2019 approved drugs in India. This will help you to understand the approved drugs that you can consumer in the form of medicine.
| S.No | Name of drug | Indication | Date of issue |
|---|---|---|---|
| 1 | For symptomatic treatment of allergic rhino-conjunctivitis (seasonal and perennial) and urticaria in adults | 1. Acute Rhinosinusitis 2. Moderate persistent asthma as an add-on therapy | 04.02.2019 |
| 2 | Bilastine tablets 20 mg and Bilastine Bulk | Iguratimod film-coated tablets 25mg and Iguratimod Bulk | 06.02.2019 |
| 3 | Iguratimod film-coated tablets 25mg and Iguratimod Bulk | For the treatment of active rheumatoid arthritis symptoms | 18.02.2019 |
| 4 | Fingolimod Capsules 0.5mg and Fingolimod hydrochloride bulk | For the treatment of patients with relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability. | 25.03.2019 |
| 5 | Remogliflozin etabonate bulk and Remogliflozin etabonate film coated tablets 100 mg | Indicated in adults aged 18 years and older with type2 diabetes mellitus to improve glycemic control as:- Monotherapy when diet and exercise alone do not provide adequate glycemic control. Add on therapy with metformin, together with diet and exercise, when these do not provide adequate glycemic control. | 26.04.2019 |
| 6 | Concentrate of Proteolytic enzyme enriched in Bromelain topical gel | Indicated for removal of eschar in adults with deep partial-and full-thickness thermal burns | 17.05.2019 |
| 7 | Menotrophin injection 600 IU/ml, 1 ml & 2 ml multi-dose vial (Highly purified) | Menotropin is indicated for the treatment of female and male infertility in the following conditions: Anovulation , including Polycystic Ovarian Disease (PCOD), in women who have been unresponsive to the treatment with Clomiphene citrate. Women undergoing controlled ovarian hyperstimulation to induce the development of multiple follicles for Assisted Reproductive Technologies (ART). Hypogonadotropic hypogonadism in men | 17.06.2019 |
| 8 | Rifapentine 150 mg film-coated tablet | “For the treatment of latent tuberculosis infection caused by Mycobacterium tuberculosis in adults and children 2 years and older who are at high risk of progression to tuberculosis disease (including those in close contact with active tuberculosis patients, recent conversion to a positive tuberculin skin test, HIV-infected patients, or those with pulmonary fibrosis on radiograph). Active tuberculosis disease should be ruled out before initiating treatment for latent tuberculosis infection. Rifapentine Tablets 150mg must always be used in combination with isoniazid as a 12-week once-weekly regimen for the treatment of latent tuberculosis infection”. | 08.07.2019 |
| 9 | FDC of Bictegravir, Emtricitabine and Tenofovir alafenamide 50mg/200mg/25mg tablets | For the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per ml) on a stable antiretroviral regimen for at least 3 months with no history of treatment failure and no known substitutions associated with resistance to Bictegravir, Emtricitabine and Tenofovir alafenamide. | 09.08.2019 |
| 10 | Levomilnacipran ER capsules 20mg/40mg/80mg/120mg | For treatment of major depressive disorder | 13.08.2019 |
| 11 | Bosutinib bulk and Bosutinib tablets 100mg, 400mg, 500mg | For the treatment of adult patients with: 1) Newly diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+CML) 2) Chronic phase, accelerated phase (AP), or blast phase (BP) Ph+CML with resistance or intolerance to prior therapy | 09.09.2019 |
| 12 | Algard – R-82 (octyl decyl dimethyl ammonium chloride 6.510 w/w + Dioctyl dimethyl ammonium chloride 2.604% w/w + Didecyl dimethyl ammonium chloride 3.906% w/w + Alkyl dimethyl benzyl ammonium chloride 8.680% w/w | Surface disinfectant for persistent disinfection of all inanimate surfaces (Against pathogens as annexed) | 09.09.2019 |
| 13 | Algard HWS-256 (didecyl dimethyl ammonium chloride 10.14% w/w + n-Alkyl dimethyl benzyl ammonium chloride 6.76% w/w | Surface disinfectant for persistent disinfection of all inanimate surfaces (Against pathogens as annexed) | 09.09.2019 |
| 14 | Safinamide methanesulfonate bulk drug and Safinamide tablets 50, 100mg | For the treatment of adult patients with idiopathic Parkinson’s disease (PD) as add-on therapy to a stable dose of Levodopa (L’Dopa) alone or in combination with other Parkinson’s disease (PD) medicinal products in mid to late-stage fluctuating patients. | 09.09.2019 |
| 15 | Droxidopa bulk drug and Droxidopa capsules 200mg/300mg | For the treatment of orthostatic dizziness, lightheadedness or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension caused by primary autonomic failure (Parkinson’s Disease multiple system atrophy (MSA) and pure autonomic failure), dopamine beta-hydroxylase deficiency and non-diabetic autonomic neuropathy. | 24.09.2019 |
| 16 | Acalabrutinib 100mg capsules | For the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy | 18.10.2019 |
| 17 | Abemaciclib 50mg, 100mg, 150mg and 200mg film-coated tablets | (i) Abemaciclib is indicated for the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. • In pre-or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. (ii) As monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting | 18.11.2019 |
| 18 | Ripasudil hydrochloride hydrate bulk drug and Ripasudil Eye drops 0.4% w/v | To treat glaucoma and ocular hypertension when other medicines for glaucoma have insufficient effects or cannot be used. | 20.11.2019 |
| 19 | Diperoxochloric acid concentrate and Diperoxochloric acid topical solution | Indicated for wound healing in diabetic neuropathic ulcers of skin and subcutaneous tissue reduction | 20.11.2019 |
| 20 | Endoxifen citrate bulk and Endoxifen tablets 8 mg | For the acute treatment of manic episodes with or without mixed features of Bipolar I disorder | 10.12.2019 |
| 21 | Azelnidipine bulk and Azelnidipine tablets 16 mg | For the treatment of Stage II Hypertension | 10.12.2019 |
| 22 | Genopep bulk and Genopep 0.05% w/w cream | Indicated for treatment of burn wound, antimicrobial therapy, scar prevention/reduction | 11.12.2019 |
| 23 | Alalevonadifloxacin mesylate bulk and Levonadifloxcin tablets 500mg | Indicated in adults (≥ 18 years of age) for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) including diabetic foot infections and concurrent bacteraemia caused by susceptible isolates of the following: Gram-positive organisms:- Staphylococcus aureus (methicillin-resistant, methicillin-susceptible, quinolone-resistant, quinolone-susceptible isolates), Streptococcus pyogenes, Enterococcus faecalis, Streptococcus dysgalactiae ssp. dysgalactiae, Streptococcus agalactiae. | 13.12.2019 |
| 24 | Midodrine hydrochloride bulk drug | 26.12.2019 | |
| 25 | Lorlatinib film-coated tablets 25mg and 100 mg | For the treatment of ALK fusion gene-positive unresectable advanced and/or recurrent non-small cell lung cancer with resistance or intolerance to ALK tyrosine kinase inhibitor(s) | 26.12.2019 |
| 26 | Levofloxacin L-arginine tetrahydrate bulk and Levofloxacin injection 800mg/100ml | Indicated in adults (≥ 18 years of age) for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) including diabetic foot infections and concurrent bacteraemia caused by susceptible isolates of the following: Gram-positive organisms:- Staphylococcus aureus (methicillin-resistant, methicillin-susceptible, quinolone-resistant, quinolone-susceptible isolates), Streptococcus pyogenes, Enterococcus faecalis, Streptococcus dysgalactiae ssp. dysgalactiae, Streptococcus agalactiae | 30.12.2019 |
How Many Drugs Were Approved in 2019?
The 48 Novel drugs were approved in the year 2019 according to the FDA Center for Drug Evaluation and Research (CDER) Annual Report: New Drug Therapy Approvals 2019. Although this approval does not cross the record of 19 drugs approvals of 2018.
FAQs
Which Drugs Were Approved for Diabetes Treatment in 2019?
The drug called Remogliflozin etabonate tablets was approved for diabetes treatment in 2019, especially for Type-2 Diabetes.
Which Drug Was Approved for Treating Glaucoma in 2019?
Ripasudil Eye Drop is a medicine that is approved for the treatment of Glaucoma and ocular hypertension.